What does Singular Genomics Systems do?

San Diego developer of the G4X high-throughput in situ spatial multiomics sequencing platform for tissue pathology research.

Who are Singular Genomics Systems's investors?

Singular Genomics Systems's investors include ARCH Venture Partners, Catalio Capital Management, LP, Coatue Management, F-Prime Capital.

Singular Genomics Systems

Acquired

Founded 2016 · 142 employees on LinkedIn · 4 known investors

Singular Genomics develops spatial pathology technology to map molecules and cells directly in tissue for disease characterization. The company serves researchers and pathologists in biomedical research and diagnostics.

Also known as Singular Genomics · Singular Genomics Systems, Inc.

Biotech Deep Tech Medical Devices

Founders & leadership

John StarkCEO

Aaron BerlinCTO

Investors · 4

ARCH Venture PartnersChicago · $50K – $250M

Catalio Capital Management, LPNew York

Coatue ManagementNew York · $1M – $20M

F-Prime CapitalCambridge · $3M – $10M

Company profile

researched Aug 2026

Singular Genomics Systems, Inc. is a San Diego, California life-science technology company developing instrumentation for spatial pathology and multiomics. Its current flagship is the G4X Spatial Sequencing Platform, a high-throughput in situ system that generates transcriptomics, proteomics and fluorescent H&E data from the same FFPE tissue section at subcellular resolution. The company positions G4X for processing large retrospective clinical sample cohorts cost-effectively, supporting AI-enabled translational research, population-scale spatial studies and 3D reconstruction from serial sections. Product materials on the company site are labelled "Product in Development. For Research Use Only."

Technically, G4X uses padlock probes with dual binding sites and rolling circle amplification for transcript detection, with in situ sequencing of each padlock probe binding region to give probe-level information rather than barcode-based readout; negative control probes and sequences are used to characterize false discovery rates. Protein detection amplifies padlock probes on oligo-conjugated antibodies followed by multiple rounds of four-color imaging, and the company reports concordance with immunofluorescence across markers and tissue types. A published demonstration profiled ten 1 cm2, 5 µm serial sections of an FFPE renal cell carcinoma sample on a single flow cell, yielding multiomic results on 6.2 million cells and 483 million transcripts, followed by clustering, automated cell-type annotation and 3D niche detection.

Earlier product lines described in secondary sources include the G4 Instrument, a benchtop next-generation sequencer with an associated consumables menu, and the PX Integrated Solution combining single-cell analysis, spatial analysis, genomics and proteomics in one instrument. The company was reported to have partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolabs, QIAGEN, Roche, Twist Bioscience and Watchmaker Genomics to validate library preparation kits on the G4, and with the Broad Institute of MIT and Harvard to connect the G4 to the Terra data platform.

Founding story

Sources conflict. One secondary source states Singular Genomics was founded in 2016 in San Diego, California by Eli Glezer and Andrew Spaventa, who brought expertise in genetics, bioinformatics and molecular biology and aimed to commercialize next-generation sequencing platforms, with a first funding round in 2019. A separate wiki-style source states the company was founded in 2010 by Steven Quake and Dino Di Carlo, both holders of PhDs in electrical engineering from Stanford University, while also stating the company was incorporated in 2016. These accounts are not reconciled by the available material.

Business model

The company designs, develops and manufactures instruments and consumables in-house and sells them to research and clinical laboratories, complemented by a services arm (Spatial Services / Technology Access Services) that runs customer samples on G4X instrumentation. Historically the model centred on selling next-generation sequencing platforms with associated menus of consumable kits, including the G4 Integrated Solution for NGS and the PX Integrated Solution for single-cell, spatial and proteomic analysis. Partnerships with reagent and automation vendors (for example Tecan Group on customized NGS library-preparation kits) support the workflow ecosystem around the instruments.

Revenue historically derived from instrument sales and recurring consumables; 2024 quarterly revenue was reported as primarily from consumables sales, alongside shipment of G4 systems. The company additionally offers fee-based spatial sequencing services on customer samples.

Traction

Reported traction includes 30 cumulative commercial G4 systems shipped as of Q1 2024 (six in that quarter); early-access sites analyzing hundreds of samples across tissue types; two named G4X Centers of Excellence (Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center); collaborations with academic groups at Harvard Medical School, Albert Einstein College of Medicine, Stanford University, University College London and the Netherlands Cancer Institute; a peer-reviewed publication in Science Immunology (January 2025) on leukemia bone marrow microenvironments; and participation in the Human Tumor Atlas Network via the VUMC GAME3D team.

Latest developments

Recent activity reported by the sources: U.S. launch of G4X in February 2026; AGBT 2026 presentations covering the G4X launch and a SPOT-Met initiative; designation of the Spatial Technologies Unit at Beth Israel Deaconess Medical Center as a G4X Center of Excellence (12 March 2026); a Center of Excellence collaboration with Vanderbilt University Medical Center supporting the HTAN Pre-Gastric Cancer program (18 March 2026); launch of the G4X Spatial Research Challenge (26 March 2026); appointment of John Stark as CEO (28 April 2026); and a reported collaboration with Tecan Group AG on customized NGS library-preparation reagent kits (May 2026). A May 2026 trade-press item reports the departure of Dr. Ropp, previously in senior leadership at the company.

▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies

Market position

Described by a secondary source as a biotechnology research company with 51-200 employees competing in genomics and spatial multiomics against established players including Illumina, Thermo Fisher Scientific, Oxford Nanopore Technologies, Qiagen, Roche, Element Biosciences and 10x Genomics. Aggregator listings also group it with QIAGEN, Bio-Rad Laboratories, Natera, Luminex, Agilent Technologies, PerkinElmer and Twist Bioscience. Reported market capitalization figures are small relative to these peers (approximately $25.18M in Q1 2024 and $50.77M in a 2026 listing), and quarterly revenue in 2024 was under $1M against net losses of $21-25M per quarter.

Sources emphasize throughput and multimodality: delivery of transcriptomics, proteomics and fluorescent H&E from the same FFPE section at subcellular resolution, section-to-section and flow-cell-to-flow-cell reproducibility supporting 3D serial-section reconstruction, and probe-level sequencing readout that permits identification and removal of individual mis-binding probes — a capability contrasted in company materials with barcoding-based approaches. Early-access users cite the ability to analyze up to 32 tissue sections per slide and to run large cohorts without sacrificing resolution or sensitivity.

Technology

In situ spatial multiomics on FFPE tissue: padlock probes with dual binding sites plus rolling circle amplification for sensitive, specific transcript detection; in situ sequencing of probe binding regions for probe-level resolution; oligo-conjugated antibodies with padlock amplification and four-color multi-round imaging for protein detection; fluorescent H&E imaging on the same section; negative control probes/sequences for false-discovery-rate measurement; and reproducibility sufficient for serial-section 3D reconstruction, unsupervised clustering, automated cell-type annotation and 3D niche detection. A 300-plex panel is referenced for sensitivity, specificity and reproducibility data, alongside off-the-shelf panels and a "Direct-Seq" capability. Reported internal tech stack includes Snowflake, Python, Cloudflare CDN, Kinsta, Smartsheet, Google Tag Manager, LinkedIn Insight Tag and Stateflow.

Go-to-market

Direct commercial launch of G4X in the U.S. (February 2026), supported by conference presence (AGBT 2026, AACR 2026, NextGen Omics Spatial & Data US 2026, Precision Medicine World Conference 2026), early-access sites and named "Centers of Excellence" at academic medical centers, a Spatial Research Challenge awarding a spatial multiomics study of up to 1,000 samples, downloadable datasets and posters, technical seminars, and a services route (Spatial Services / Technology Access Services) that lets prospective customers generate G4X data on their own samples before purchase.

Translational and clinical researchers, pathologists and academic medical centers running large tissue cohorts — including cancer research groups (head and neck, kidney, lung, breast, colon, gastric pre-cancer, AML bone marrow), consortium and atlas programs such as the Human Tumor Atlas Network, and clinical trial and biomarker discovery efforts.

Geography

Headquarters and address given as 3010 Science Park Rd, San Diego, CA 92121; one secondary source lists the headquarters as La Jolla, California. One data-aggregator source states employees are spread across three continents (North America, Asia, South America). Customers and collaborators cited include U.S. institutions (Beth Israel Deaconess Medical Center, Vanderbilt University Medical Center, Harvard Medical School, Albert Einstein College of Medicine, Stanford University) and European institutions (University College London, Netherlands Cancer Institute).

History

Sources give conflicting founding accounts: multiple sources state the company was incorporated/founded in 2016 in San Diego, California, with one source naming Eli Glezer and Andrew Spaventa as founders, while another wiki-style source states it was founded in 2010 by Steven Quake and Dino Di Carlo. A first funding round is reported in 2019, followed by a $131M round on 12 May 2021, and the company traded publicly under the ticker OMIC. Its first product, the G4 Sequencing Platform, debuted in 2020; the G4X Spatial Sequencer followed in 2024. Reagent and workflow partnerships were signed with Watchmaker Genomics (January 2022), Paragon Genomics and Claret Bioscience (November 2022) and Tecan Group (2023, integrating MagicPrep NGS with G4). In June 2024 the company carried out a 1-for-30 reverse stock split to maintain Nasdaq listing compliance. Acquisition by Deerfield Management closed on 21 February 2025, taking the company private to accelerate technology commercialization. Through 2025-2026 the company concentrated on spatial multiomics, launching G4X in the U.S. in February 2026, naming Centers of Excellence at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, and appointing John Stark CEO in April 2026.

Risks & controversies

Financial scale and losses: quarterly revenue below $1M in 2024 against net losses of $25.0M (Q1) and $21.3M (Q2), and a 1-for-30 reverse stock split in June 2024 to meet Nasdaq listing requirements. Sources also report that on 18 December 2025 dark web monitoring sites named Singular Genomics as a data breach victim. Company materials label the product as in development and for research use only. Source records are inconsistent on founding date, founders and headquarters city, and on whether the company remains publicly traded following the February 2025 Deerfield acquisition.

Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.